SCHEMBL6086503

SCHEMBL6086503

NC(=O)C1OC(=C2C(=O)Nc3ccccc32)c2c[c]ccc21

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
PKM P14618 1/20 0.33
MAPK1 P28482 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
LRRK2 Q5S007 3/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
PDGFRA P16234 1/20 0.33
FER P16591 1/20 0.33
LTK P29376 1/20 0.33
CDK8 P49336 1/20 0.33
ACVR1 Q04771 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
NTRK1 P04629 1/20 0.32
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
CCNA1 P78396 1/20 0.32
IDO1 P14902 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086021 0.87 ALDH1A1 (0.38) ALDH1A1MAPTKDM4EPKMMAPK1
SCHEMBL14725083 0.76 LRRK2 (0.39) ALDH1A1MAPTKDM4EPKMMAPK1
SCHEMBL6086479 0.76 LRRK2 (0.39) ALDH1A1MAPTKDM4EPKMMAPK1
SCHEMBL6086475 0.76 LRRK2 (0.39) ALDH1A1MAPTKDM4EPKMMAPK1
SCHEMBL3880165 0.75 ATM (0.31)
SCHEMBL6086705 0.71 HSD17B10 (0.46) ALDH1A1MAPTKDM4EPKMMAPK1
SCHEMBL6086708 0.71 HSD17B10 (0.46) ALDH1A1MAPTKDM4EPKMMAPK1
SCHEMBL14725043 0.67 TAOK1 (0.35) ALDH1A1MAPTKDM4EPKMMAPK1
SCHEMBL6087420 0.67 TAOK1 (0.35) ALDH1A1MAPTKDM4EPKMMAPK1
SCHEMBL6087424 0.67 TAOK1 (0.35) ALDH1A1MAPTKDM4EPKMMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP claimed
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2004-01-29 US claimed
US-6541504-B1 Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. ALLERGAN SALES, LLC 2003-04-01 US claimed
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP disclosed
US-7060844-B2 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-06-13 US disclosed
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2004-01-29 US disclosed
US-6541504-B1 Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. ALLERGAN SALES, LLC 2003-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 ALDH1A1 1606/4885MAPT 2710/4885KDM4E 1176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.